Trevi Therapeutics, Inc.
TRVI
$16.64
-$0.18-1.07%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -44.68% | -27.58% | 27.15% | 10.87% | 0.41% |
| Total Depreciation and Amortization | -10.53% | -8.11% | -18.42% | 5.56% | 0.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 157.16% | 101.62% | 10.27% | 111.87% | 22.90% |
| Change in Net Operating Assets | -340.06% | -31.64% | -127.16% | -105.36% | -61.46% |
| Cash from Operations | -72.55% | -23.83% | 20.09% | -13.86% | -16.33% |
| Capital Expenditure | -- | -- | 100.00% | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -4,187.89% | 271.51% | -28.25% | -764.22% | -193.35% |
| Cash from Investing | -4,192.64% | 270.49% | -28.22% | -764.38% | -194.29% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | 100.00% | 100.00% | 100.00% |
| Issuance of Common Stock | 48.79% | -97.52% | -99.45% | -77.58% | 2,072.68% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -20.92% | -- | -- | -- | -- |
| Cash from Financing | 48.88% | -97.45% | -99.45% | -67.28% | 2,078.71% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -64.28% | 103.38% | -310.34% | -2,048.49% | 11,619.34% |